Head-to-head survey: enGene (ENGN) and colleagues

enGene (NASDAQ:ENGN – Get Free Report) is one of 440 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare enGene to related companies based on the strength of its profitability, valuation, dividends, risk, institutional ownership, earnings and analyst recommendations.

Rating and Earnings

This table compares enGene’s revenue, earnings per share (EPS) and valuation to its competitors.

enGene’s competitors have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and risk

enGene has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 1.21, indicating that their price the stock average is 21% more volatile than the S&P 500.

dividends

enGene pays an annual dividend of $1.58 per share and has a dividend yield of 26.8%. enGene pays out -97.0% of its earnings as a dividend. As a group, biotech companies pay a dividend yield of 3.1% and pay out 3,469.2% of earnings in dividends. enGene is clearly a better dividend stock than its competitors given its higher yield and lower payout ratio.

Institutional and insider ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 31.1% of shares of all biotech companies are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 22.6% of shares of all “biotech” companies are held by insiders. Strong institutional ownership is an indication that endowments, big money managers and hedge funds believe a company is poised for long-term growth.

Analyst recommendations

This is a breakdown of current recommendations and price targets for enGene and its competitors, as reported by MarketBeat.com.

enGene presently has a consensus target price of $34.40, indicating a potential upside of 483.05%. As a group, “biotech” companies have a potential upside of 14.50%. Given enGene’s stronger consensus rating and higher probable upside, research analysts plainly believe enGene is more favorable than its competitors.

return

This table compares enGene and its competitors’ net margins, return on equity and return on assets.

Summary

enGene beats its competitors in 10 of the 15 factors compared.

enGene Company Profile

(Get a free report)

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops gene medicines by delivering drugs to mucosal tissues and other organs. Its lead product candidate is EG-70 (voraplasmid detalimogene), which is a non-viral immunotherapy for the treatment of patients with non-muscle-invasive bladder cancer with carcinoma in situ (CIS) unresponsive to Bacillus Calmette-Guérin treatment . The company was founded in 2023 and is based in Saint-Laurent, Canada.

Get news and reviews for enGene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for enGene and related companies with MarketBeat.com’s FREE daily email newsletter.